Fibroblast growth factor 20 ameliorates cardiac hypertrophy via activation ErbB2
Yunjie Chen,
Xuan Zhou,
Xu Wang,
Yuanbin Zhang,
Jiayi Song,
Yan Cai,
Yizhuo Zhao,
Lin Mei,
Suyan Zhu,
Xueqin Chen
Affiliations
Yunjie Chen
Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China
Xuan Zhou
Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China
Xu Wang
School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China
Yuanbin Zhang
Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China
Jiayi Song
Reproductive Medicine Center, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China
Yan Cai
Department of Clinical Pharmacy, Ningbo Ninth Hospital, Ningbo, 315020, Zhejiang, China
Yizhuo Zhao
Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China
Lin Mei
Department of Pharmacy, Xiamen Medical College, Xiamen, 361000, Fujian, China
Suyan Zhu
Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China; Corresponding author. Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China.
Xueqin Chen
Department of Traditional Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China; Corresponding author. Department of Traditional Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China.
Fibroblast growth factor 20 (FGF20) is a member of the fibroblast growth factor family and involved in embryonic development and cardiac repair. This study aimed to explore the role of FGF20 in cardiac hypertrophy and the underlying molecular mechanisms. FGF20 improved cardiac hypertrophy in vivo and in vitro. Furthermore, FGF20 increased expression of erythroblastic leukemia viral oncogene homolog 2 (ErbB2), which was negatively correlated with expression of the cardiac hypertrophy markers atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). In addition, FGF20 effectively protected cardiomyocytes against apoptosis and oxidative stress. To further investigate whether protective effect of FGF20 is mediated by ErbB2, neonatal rat cardiomyocytes (NRCMs) were treated with lapatinib, an inhibitor of ErbB2. Lapatinib largely abrogated the anti-hypertrophic effect of FGF20, accompanied by increases in cardiomyocyte apoptosis and oxidative stress. In summary, this study reveals that FGF20 prevents cardiac hypertrophy by inhibiting apoptosis and oxidative stress via activating ErbB2 and may be a promising therapeutic strategy for cardiac hypertrophy.
